IL144995A0 - Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders - Google Patents
Recombinant il-18 antagonists useful in treatment of il-18 mediated disordersInfo
- Publication number
- IL144995A0 IL144995A0 IL14499500A IL14499500A IL144995A0 IL 144995 A0 IL144995 A0 IL 144995A0 IL 14499500 A IL14499500 A IL 14499500A IL 14499500 A IL14499500 A IL 14499500A IL 144995 A0 IL144995 A0 IL 144995A0
- Authority
- IL
- Israel
- Prior art keywords
- recombinant
- treatment
- mediated disorders
- antagonists useful
- antagonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12529999P | 1999-03-19 | 1999-03-19 | |
PCT/US2000/007349 WO2000056771A1 (en) | 1999-03-19 | 2000-03-17 | Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144995A0 true IL144995A0 (en) | 2002-06-30 |
Family
ID=22419067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14499500A IL144995A0 (en) | 1999-03-19 | 2000-03-17 | Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders |
Country Status (28)
Country | Link |
---|---|
US (2) | US6706487B1 (zh) |
EP (2) | EP1163271B1 (zh) |
JP (1) | JP2002542769A (zh) |
KR (1) | KR100697120B1 (zh) |
CN (1) | CN1246335C (zh) |
AR (1) | AR022952A1 (zh) |
AT (1) | ATE402191T1 (zh) |
AU (1) | AU764622B2 (zh) |
BR (1) | BR0008688A (zh) |
CA (1) | CA2368965C (zh) |
CO (1) | CO5470287A1 (zh) |
CY (1) | CY1108387T1 (zh) |
CZ (1) | CZ303704B6 (zh) |
DE (1) | DE60039589D1 (zh) |
DK (1) | DK1163271T3 (zh) |
ES (1) | ES2308974T3 (zh) |
HK (1) | HK1043798B (zh) |
HU (1) | HU228931B1 (zh) |
IL (1) | IL144995A0 (zh) |
MY (1) | MY124219A (zh) |
NO (1) | NO330391B1 (zh) |
NZ (1) | NZ513699A (zh) |
PL (1) | PL202396B1 (zh) |
PT (1) | PT1163271E (zh) |
SI (1) | SI1163271T1 (zh) |
TR (3) | TR200202253T2 (zh) |
WO (1) | WO2000056771A1 (zh) |
ZA (1) | ZA200107639B (zh) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852266A (en) * | 1993-07-14 | 1998-12-22 | Hitachi, Ltd. | Vacuum circuit breaker as well as vacuum valve and electric contact used in same |
IL121860A0 (en) | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
US7220717B2 (en) | 1997-08-14 | 2007-05-22 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use |
US7704944B2 (en) | 1997-08-14 | 2010-04-27 | Yeda Research And Development Company Ltd. | Interleukin-18 binding proteins, their preparation and use for the treatment of sepsis |
CA2276216A1 (en) * | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
US7229619B1 (en) | 2000-11-28 | 2007-06-12 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
US6656467B2 (en) * | 2000-01-27 | 2003-12-02 | Medimmune, Inc. | Ultra high affinity neutralizing antibodies |
NZ520392A (en) * | 2000-02-10 | 2005-04-29 | Abbott Lab | Antibodies that bind human interleukin-18 and methods of making and using |
KR20020086540A (ko) * | 2000-02-21 | 2002-11-18 | 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. | Il-18 저해물질의 용도 |
AU2002224417A1 (en) * | 2000-10-18 | 2002-04-29 | Immunex Corporation | Methods for treating il-18 mediated disorders |
US7179900B2 (en) | 2000-11-28 | 2007-02-20 | Medimmune, Inc. | Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment |
WO2003083071A2 (en) * | 2002-03-26 | 2003-10-09 | Centocor, Inc. | Diabetes-related immunoglobulin derived proteins, compositions, methods and uses |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
WO2004040969A1 (ja) * | 2002-11-07 | 2004-05-21 | Kumamoto Technology & Industry Foundation | Ganp導入トランスジェニック哺乳動物及びその利用 |
CA2523912A1 (en) | 2003-04-30 | 2004-11-11 | Japan Science And Technology Agency | Human antihuman interleukin-18 antibody, fragment thereof and method of using the same |
US7968684B2 (en) | 2003-11-12 | 2011-06-28 | Abbott Laboratories | IL-18 binding proteins |
US20050100965A1 (en) * | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
AU2011224023C1 (en) * | 2003-11-12 | 2013-08-29 | Abbvie Inc. | IL-18 binding proteins |
US7141382B1 (en) | 2004-10-12 | 2006-11-28 | Parikh Chirag R | Methods for detection of IL-18 as an early marker for diagnosis of acute renal failure and predictor of mortality |
EP2532678A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
NZ572565A (en) * | 2006-05-25 | 2011-04-29 | Glaxo Group Ltd | Modified humanised anti-interleukin-18 antibodies |
GB0610438D0 (en) * | 2006-05-25 | 2006-07-05 | Glaxo Group Ltd | Immunoglobulins |
EP1997830A1 (en) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | RSV specific binding molecules and means for producing them |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
CN101883790B (zh) | 2007-10-05 | 2015-09-09 | 基因技术公司 | 抗淀粉样蛋白β抗体在眼病中的用途 |
US20100291071A1 (en) * | 2008-08-01 | 2010-11-18 | Immunas Pharma, Inc. | Antibody Specific Binding to A-Beta Oligomer and the Use |
CN101965365A (zh) * | 2007-10-19 | 2011-02-02 | 伊缪纳斯制药株式会社 | 能够特异性结合Aβ寡聚体的抗体及其应用 |
CA2714413C (en) * | 2008-02-08 | 2017-01-24 | Immunas Pharma, Inc. | Antibody capable of binding specifically to ab-oligomer, and use thereof |
EP2281004A4 (en) * | 2008-04-14 | 2012-02-15 | Proscan Rx Pharma Inc | PROSTATE-SPECIFIC MEMBRANANT ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS |
US9085614B2 (en) | 2008-08-01 | 2015-07-21 | Immunas Pharma, Inc. | Antibodies that specifically bind to Aβ oligomers and uses thereof |
US20110150871A1 (en) * | 2008-08-18 | 2011-06-23 | Glaxo Group Limited | Treatment of an autoimmune disease using il-18 antagonists |
WO2010040736A2 (en) * | 2008-10-07 | 2010-04-15 | Ablynx Nv | Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling |
US8168165B2 (en) * | 2008-12-23 | 2012-05-01 | Abbott Laboratories | Alkylated interleukin-18 compositions |
EP2419447B1 (en) | 2009-04-17 | 2017-08-23 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
CN102196840A (zh) * | 2009-06-30 | 2011-09-21 | 株式会社高纤 | 球拍用线及其制造方法以及拉设有该球拍用线的球拍 |
DK2462161T3 (en) | 2009-08-06 | 2017-06-06 | Immunas Pharma Inc | Antibodies specifically binding to A-beta oligomers and their use |
WO2011016239A1 (en) | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
TWI465250B (zh) | 2009-08-29 | 2014-12-21 | Abbvie Inc | 治療用之dll4結合蛋白質 |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
EP2534175A2 (en) * | 2010-02-09 | 2012-12-19 | Glaxo Group Limited | Treatment of a metabolic disorder |
WO2011106697A1 (en) | 2010-02-25 | 2011-09-01 | Schepens Eye Research Institute | Therapeutic compositions for the treatment of dry eye disease |
EP2542582A4 (en) * | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
WO2011150086A2 (en) * | 2010-05-25 | 2011-12-01 | The Regents Of The University Of Colorado, A Body Corporate | Diagnosis and treatment of autoimmune disease |
RU2607368C2 (ru) | 2010-07-30 | 2017-01-10 | Ац Иммуне С.А. | Безопасные и функциональные гуманизированные антитела |
EP2655416A1 (en) | 2010-12-20 | 2013-10-30 | Medimmune Limited | Anti-il-18 antibodies and their uses |
JOP20200308A1 (ar) | 2012-09-07 | 2017-06-16 | Novartis Ag | جزيئات إرتباط il-18 |
EP2924117B1 (en) | 2012-11-21 | 2019-08-14 | KM Biologics Co., Ltd. | Novel human antibody against il-18 |
RU2755691C2 (ru) * | 2015-03-05 | 2021-09-20 | Аб2 Био Са | Il-18-связывающие белок (il-18bp) и антитела при воспалительных заболеваниях |
JP2023530489A (ja) * | 2020-06-18 | 2023-07-18 | ネクストキュア インコーポレイテッド | Flrt3媒介性シグナル伝達を調節するための組成物及び方法 |
JPWO2023286694A1 (zh) | 2021-07-13 | 2023-01-19 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
EP0528767B1 (en) | 1991-08-21 | 2000-01-12 | Novartis AG | Antibody derivatives |
GB9125979D0 (en) * | 1991-12-06 | 1992-02-05 | Wellcome Found | Antibody |
TW581771B (en) | 1994-11-15 | 2004-04-01 | Hayashibara Biochem Lab | Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide |
IL121860A0 (en) * | 1997-08-14 | 1998-02-22 | Yeda Res & Dev | Interleukin-18 binding proteins their preparation and use |
FR2767697B1 (fr) | 1997-09-01 | 2000-05-05 | Boots Co Plc | Composition dermatologique permettant d'eviter l'apparition de symptomes d'hypersensibilite et d'intolerance cutanee |
CA2276216A1 (en) | 1998-06-24 | 1999-12-24 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | An artificial peptide capable of neutralizing the biological activity of interleukin-18 |
AR022952A1 (es) * | 1999-03-19 | 2002-09-04 | Smithkline Beecham Corp | ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL |
-
2000
- 2000-03-16 AR ARP000101168A patent/AR022952A1/es active IP Right Grant
- 2000-03-17 TR TR2002/02253T patent/TR200202253T2/xx unknown
- 2000-03-17 TR TR2002/02254T patent/TR200202254T2/xx unknown
- 2000-03-17 NZ NZ513699A patent/NZ513699A/xx not_active IP Right Cessation
- 2000-03-17 ES ES00918152T patent/ES2308974T3/es not_active Expired - Lifetime
- 2000-03-17 JP JP2000606631A patent/JP2002542769A/ja active Pending
- 2000-03-17 HU HU0200502A patent/HU228931B1/hu unknown
- 2000-03-17 US US09/914,695 patent/US6706487B1/en not_active Expired - Lifetime
- 2000-03-17 SI SI200031002T patent/SI1163271T1/sl unknown
- 2000-03-17 PT PT00918152T patent/PT1163271E/pt unknown
- 2000-03-17 CZ CZ20013362A patent/CZ303704B6/cs not_active IP Right Cessation
- 2000-03-17 MY MYPI20001044A patent/MY124219A/en unknown
- 2000-03-17 KR KR1020017011872A patent/KR100697120B1/ko active IP Right Grant
- 2000-03-17 EP EP00918152A patent/EP1163271B1/en not_active Expired - Lifetime
- 2000-03-17 WO PCT/US2000/007349 patent/WO2000056771A1/en active IP Right Grant
- 2000-03-17 EP EP08157217A patent/EP1961768A1/en not_active Withdrawn
- 2000-03-17 CA CA2368965A patent/CA2368965C/en not_active Expired - Lifetime
- 2000-03-17 PL PL350460A patent/PL202396B1/pl unknown
- 2000-03-17 DK DK00918152T patent/DK1163271T3/da active
- 2000-03-17 BR BR0008688-6A patent/BR0008688A/pt not_active Application Discontinuation
- 2000-03-17 AT AT00918152T patent/ATE402191T1/de active
- 2000-03-17 DE DE60039589T patent/DE60039589D1/de not_active Expired - Lifetime
- 2000-03-17 IL IL14499500A patent/IL144995A0/xx not_active IP Right Cessation
- 2000-03-17 CN CNB008077703A patent/CN1246335C/zh not_active Expired - Lifetime
- 2000-03-17 AU AU39016/00A patent/AU764622B2/en not_active Expired
- 2000-03-17 CO CO00019489A patent/CO5470287A1/es active IP Right Grant
- 2000-03-17 TR TR2001/02733T patent/TR200102733T2/xx unknown
-
2001
- 2001-09-17 ZA ZA200107639A patent/ZA200107639B/en unknown
- 2001-09-18 NO NO20014524A patent/NO330391B1/no not_active IP Right Cessation
-
2002
- 2002-05-21 HK HK02103813.7A patent/HK1043798B/zh not_active IP Right Cessation
-
2004
- 2004-01-22 US US10/762,629 patent/US20040141964A1/en not_active Abandoned
-
2008
- 2008-09-30 CY CY20081101085T patent/CY1108387T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL350460A1 (en) | Recombinant il-18 antagonists useful in treatment of il-18 mediated disorders | |
HUS1500070I1 (hu) | IL-5-Mediált rendellenességek kezelésére használható rekombináns IL-5 antagonisták | |
HK1109867A1 (en) | Arylsulfonamide derivatives for use as ccr3 antagonists in the treatment of inflammatory and immunological disorders | |
HK1152243A1 (zh) | 用於治療中樞神經系統疾病的 | |
HK1068885A1 (en) | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases n-- | |
AU6861001A (en) | 1,3-bis-(substituted-phenyl)-2-propen-1-ones and their use to treat vcam-1 mediated disorders | |
HK1079203A1 (en) | Substituted amine derivatives and methods of use in the treatment of angiogenesis related disorders | |
IL144954A0 (en) | Quinazolines and therapeutic use thereof | |
IL157365A0 (en) | Mch antagonists and their use in the treatment of obesity | |
GB0007193D0 (en) | Treatment of movrmrnt disorders | |
EP1404343A4 (en) | THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF HORMONE DEFICIENCIES | |
IL149496A0 (en) | Pharmaceutical combinations and their use in treating gastrointestinal disorders | |
IL161267A0 (en) | Combinations for the treatment of immunoinflammatory disorders | |
IL156781A0 (en) | (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes | |
EP1416957A4 (en) | TREATMENT OF IMMUNE DISEASES AND B-CELL DISEASES | |
PL369822A1 (en) | Use of endothelin receptor antagonists in the treatment of tumour diseases | |
AU2003250831A8 (en) | Use of hec1 antagonists in the treatment of proliferative disorders and cancer | |
PL351554A1 (en) | Osanetant in the treatment of mood disorders | |
HUP0202339A3 (en) | Use of cortisol antagonists in the treatment of heat failure | |
PL347976A1 (en) | Isonipecotamides for the treatment of integrin−mediated disorders | |
AU6330300A (en) | Use of interleukin-6 in treatment of obesity and/or obesity associated disorders | |
SI0800536T1 (sl) | Rekombinantni antagonisti il-5 uporabni za zdravljenje motenj povezanih z delovanjem il-5 | |
IL160551A0 (en) | Plaster for the treatment of dysfunctions and disorders of nails | |
AU2002229091A1 (en) | Secreted polypeptide and their use in the treatment of bone disorders | |
HUP0200775A3 (en) | Use of pegylated interferon-alpha in melanoma therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXP | Patent expired |